Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetic Macular Edema
Biotech
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka, securing $85 million in cash to fund the asset’s phase 3 development.
James Waldron
Oct 31, 2025 5:09am
4DMT climbs as gene therapy patients keep jettisoning jabs
Aug 1, 2025 5:35am
Unity's stock tumbles after eye treatment fails to match Eylea
Mar 24, 2025 11:11am
Aviceda raises $207M for geographic atrophy drug's ph. 3 journey
Jan 7, 2025 9:38am
Merck has clear vision to eye disease assets with $3B EyeBio buy
May 29, 2024 8:32am
Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up
May 22, 2024 7:15am
